Allergy Immunotherapy Market Outlook:
Allergy Immunotherapy Market size was over USD 4 billion in 2025 and is estimated to reach USD 6 billion by the end of 2035, exhibiting a CAGR of 4.5% during the forecast period, i.e., 2026-2035. In 2026, the industry size of allergy immunotherapy is assessed at 4.1 billion.
The demand for the market is growing on account of the increasing incidence of allergic diseases globally. According to the January 2023 CDC report, almost 25.7% of the U.S. population indicated they had a history of seasonal allergies in 2021. Additionally, the NLM article in July 2023 states that 50 million U.S. people are affected by allergic rhinitis, and 20 to 30 million are affected by asthma, causing allergy component. This further creates a heightened awareness among both healthcare professionals and patients, intensifying the therapeutic demand.
Furthermore, the supply chain for the products in allergy immunotherapy comprises raw material sourcing, active pharmaceutical ingredients, biologic manufacturing, and medical device development, such as injection devices for subcutaneous immunotherapy. These APIs and vaccines are imported from regions with substantial manufacturing capabilities. In this context, import-export activities from the CEIC data in 2023 demonstrated a lucrative increase in import activities that with U.S. imports of pharmaceutical products reported at USD 90,202,040.529 in December 2023.
